Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

Share Price Information for Alliance Pharma (APH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 35.00
Bid: 35.00
Ask: 35.40
Change: -0.15 (-0.43%)
Spread: 0.40 (1.143%)
Open: 35.00
High: 35.35
Low: 35.00
Prev. Close: 35.15
APH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Dealings

19 Jul 2023 07:00

RNS Number : 4343G
Alliance Pharma PLC
19 July 2023
 

 

19 July 2023

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

 

Director Dealings

 

Alliance Pharma plc (AIM: APH), the international healthcare group, has been notified that Andrew Franklin, the Chief Financial Officer of the Company, purchased 50,988 ordinary shares of 1.0p each in the Company ("Ordinary Shares") at a price of 49.005 pence per share on 18th July 2023; and Richard Jones, a non-executive Director of the Company, purchased 53,000 Ordinary Shares at a price of 47.10 pence per share on 18th July 2023.

 

Following this transaction, (i) Mr. Franklin's total beneficial interest in the Company is 179,372 Ordinary Shares, representing 0.03% of the Company's issued share capital; and (ii) Mr. Jones' total beneficial interest in the Company is 68,000 Ordinary Shares, representing 0.013% of the Company's issued share capital.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Andrew Franklin

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Alliance Pharma Plc

b)

Legal Entity Identifier

213800RYIWZA4Q5WPZ13

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1 pence each

 

GB0031030819

 

b)

Nature of the transaction

Purchase of shares

c)

Currency

GBP

 

d)

Price(s) and volume(s)

Price(s)

Volume(s)

49.005

50,988

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 50,988 Ordinary Shares, bought at a price of 49.005 pence per share, totalling £24,986.67

 

f)

Date of the transaction

18 July 2023

g)

Place of the transaction

London Stock Exchange, AIM

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Richard Jones

2

Reason for the notification

a)

Position/status

Non Executive Director

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Alliance Pharma Plc

b)

Legal Entity Identifier

213800RYIWZA4Q5WPZ13

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1 pence each

 

GB0031030819

 

b)

Nature of the transaction

Purchase of shares

c)

Currency

GBP

 

d)

Price(s) and volume(s)

Price(s)

Volume(s)

47.10

53,000

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

53,000 Ordinary Shares, bought at a price of 47.10 pence per share, totalling £24,963

 

f)

Date of the transaction

18 July 2023

g)

Place of the transaction

London Stock Exchange, AIM

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Cora McCallum, Head of Investor Relations & Corporate Communications

+ 44 (0)1249 705168

ir@allianceph.com

Buchanan

+ 44 (0)20 7466 5000

Mark Court / Hannah Ratcliff

alliancepharma@buchanan.uk.com

Numis Securities Limited (Nominated Adviser and Joint Broker)

+ 44 (0)20 7260 1000

Freddie Barnfield / Duncan Monteith / Sher Shah

Investec Bank plc (Joint Broker)

+ 44 (0)20 7597 5970

Patrick Robb / Maria Gomez de Olea

 

 

About Alliance

 

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands.

For more information on Alliance, please visit our websitewww.alliancepharmaceuticals.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBIGDRCBBDGXI
Date   Source Headline
31st Aug 20075:21 pmRNSMajor Interest in Shares
31st Aug 20078:36 amRNSMajor Interest in Shares
13th Aug 200710:45 amRNSAIM Rule 26
27th Jul 200711:20 amRNSGrant of Options
23rd Jul 20077:00 amRNSPositive Isprelor Results
11th Jul 20077:00 amRNSHalf Year Trading Update
28th Jun 20077:01 amRNSAppt of Finance Director
13th Jun 20077:02 amRNSCost Control Programme
16th May 20079:58 amRNSAGM Statement
22nd Mar 20077:04 amRNSForceval China Rights
22nd Mar 20077:03 amRNSPreliminary Results
27th Feb 20077:01 amRNSNotification of Shares
19th Feb 20071:56 pmRNSNotification of Shares
15th Jan 20077:01 amRNSTrading and Product Update
10th Jan 20077:00 amRNSBoard Appointment
19th Dec 20064:52 pmRNSTransparency Directive
23rd Oct 20067:01 amRNSSyntometrine Acquisition
18th Sep 200610:01 amRNSDirector/PDMR Shareholding
15th Sep 20067:00 amRNSProduct Acquisition
13th Sep 20067:01 amRNSInterim Results
8th Aug 20067:01 amRNSNotice of Interim Results
6th Jul 20067:00 amRNSPfizer Products Acquisition
20th Jun 20067:03 amRNSConference Presentation
8th Jun 20067:01 amRNSAppointment
22nd May 20067:00 amRNSDistribution Agreement
18th May 20062:43 pmRNSMajor Interests in Shares
18th May 20067:02 amRNSDermatology Acquisition
17th May 20067:01 amRNSNotification of Interests
12th May 200610:19 amRNSAGM Statement
10th May 20067:00 amRNSPlacing to raise GBP2.5m
28th Apr 20067:03 amRNSLondon symposium on Melatonin
23rd Mar 20067:03 amRNSPreliminary Results
21st Mar 20062:07 pmRNSInterest in Major Shares
2nd Mar 20067:00 amRNSNotice of Results
9th Feb 20061:05 pmRNSHydromol Acquisition
10th Jan 20067:00 amRNSTrading Statement
12th Dec 20057:02 amRNSBiotech Investment Forum
3rd Nov 20057:02 amRNSInterim Results
3rd Nov 20057:00 amRNSProduct Disposal
11th Oct 200511:21 amRNSResults Notification
30th Sep 20057:03 amRNSMisoprostol Symposium
19th Sep 20057:02 amRNSAppointment
1st Aug 20057:00 amRNSNotification of Shares
29th Jul 20057:00 amRNSDistribution Agreement
13th Jul 200510:11 amRNSNotification of Shares
6th Jul 20057:00 amRNSPhase III Trials Approval
24th Jun 20057:00 amRNSNotice of Interests in Shares
21st Jun 200510:52 amRNSAGM Statement
17th May 20057:00 amRNSShare Purchase
16th May 200512:35 pmRNSDirector Share Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.